Author(s):
Snehal Gawai, Nilakshi Dhoble, Priyanka Mandal, Nitin Padole, Pankaj Dhapake, Jagdish R. Baheti
Email(s):
snehalgawai0630@gmail.com , dhoblenn18@gmail.com
DOI:
10.52711/0974-360X.2024.00897 
Address:
Snehal Gawai*, Nilakshi Dhoble, Priyanka Mandal, Nitin Padole, Pankaj Dhapake, Jagdish R. Baheti
Kamla Nehru College of Pharmacy, Butibori, Nagpur
Borkhedi Gate, Near Railway Crossing, Butibori, Nagpur, 441108.
*Corresponding Author
Published In:
Volume - 17,
Issue - 12,
Year - 2024
ABSTRACT:
The purpose of this study is to prepare a bilayer tablet of Celecoxib using wet granulation technology and to formulate an optimized formulation. Celecoxib is a non-steroidal anti-inflammatory drug that inhibits the prostaglandin-generating enzyme cyclo-oxygenase 2 and reduces the pain and inflammation of Osteoarthritis. Fast release of the drug from the immediate-release layer can give a rapid onset of action which will help to reduce pain and inflammation within a short period while the maintenance dose of Celecoxib will maintain plasma concentration within the therapeutic range for 24 hours. Permeability enhancers such as Chitosan were used, which can increase the permeability as well as bioavailability of the drug. In this study, a bilayer tablet was prepared which contains an immediate release layer and a sustained release layer. HPMC K100 was used to maintain sustained release and Croscarmellose Sodium for immediate release. Sodium Starch Glycolate and Cross Povidone were used as super disintegrants. The bilayer tablets were tested for weight variation, hardness, friability, thickness, drug content, in-vitro dissolution profile, bulk density, tapped density, angle of repose, carr’s index, Hausner's ratio, and calibration curve. The granules showed satisfactory flow properties and compressibility. The best formulation L5 showed a High % drug release 96.04% release, high drug content, high hardness, and friability. Bilayer tablet is enhancing beneficial technology to control the shortcomings of the single-layered tablet. The aim of designing sustained or controlled delivery systems is to decrease the repetition of the dosing or to increase the effectiveness of the drug by localization at the site of action, lowering the dose required, or providing uniform drug delivery. The main objective of sustained release drug delivery is to make sure safety and to improve patient compliance.
Cite this article:
Snehal Gawai, Nilakshi Dhoble, Priyanka Mandal, Nitin Padole, Pankaj Dhapake, Jagdish R. Baheti. Development and Evaluation of bi-layer Tablet Containing Sustained-Release and Immediate Release Celecoxib. Research Journal Pharmacy and Technology. 2024;17(12):5915-2. doi: 10.52711/0974-360X.2024.00897
Cite(Electronic):
Snehal Gawai, Nilakshi Dhoble, Priyanka Mandal, Nitin Padole, Pankaj Dhapake, Jagdish R. Baheti. Development and Evaluation of bi-layer Tablet Containing Sustained-Release and Immediate Release Celecoxib. Research Journal Pharmacy and Technology. 2024;17(12):5915-2. doi: 10.52711/0974-360X.2024.00897 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-12-34
REFERENCES:
1. Tanaji D. Nandgude, Priyajit S. Hasabe, Anuja K. Kolsure. Clinical Features and Treatment of Rheumatoid Arthritis: A Review. Research J. Pharm. and Tech. 2018; 11(12): 5701-5706. doi: 10.5958/0974-360X.2018.01032.6 https://doi.org/10.5958/0974-360X.2018.01032.6
2. Mandl LA. Osteoarthritis year in review 2018: clinical. Osteoarthritis and cartilage. 2019; Mar 1; 27(3): 359-364. https://doi.org/10.1016/j.joca.2018.11.001
3. Kloppenburg M, Berenbaum F. Osteoarthritis year in review 2019: epidemiology and therapy. Osteoarthritis and cartilage. 2020; Mar 1; 28(3): 242-248. https://doi.org/10.1016/j.joca.2020.01.002
4. Pagar KR, Khandbahale SV, Kasar PM. Osteoarthritis: Pathophysiology and current treatment modalities. Asian Journal of Pharmaceutical Research. 2019; Oct; 9(4): 289-298.
5. Cooper C, Chapurlat R, Al-Daghri N, Herrero-Beaumont G, Bruyère O, Rannou F, Roth R, Uebelhart D, Reginster JY. Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: what does the literature say?. Drugs and aging. 2019; Apr 1; 36(Suppl 1): 15-24 https://doi.org/10.1007/s40266-019-00660-1
6. Malfait, A.M. and Schnitzer, T.J. Towards a mechanism-based approach to pain management in osteoarthritis. Nature Reviews Rheumatology. 2013; 9(11): 654-664. https://doi.org/10.1038/nrrheum.2013.138
7. Chaudhary A, Pandit V, Ashawat MS, Kumar T. Rheumatoid arthritis, a laconic review to understand their basic concept and management process. Asian Journal of Pharmaceutical Research. 2022; 12(4): 312-22. http://dx.doi.org/10.52711/2231-5691.2022.00051
8. Mourya H, Chauhan R, Joshi R, Akram W, Garud N. Bilayer tablets: A promising novel drug delivery system. Research Journal of Pharmacy and Technology. 2023; 16(5): 2517-21. http://dx.doi.org/10.52711/0974-360X.2023.00414
9. George N, Pillai MK, Haribabu Y. Bilayer floating tablets: An updated review. Research Journal of Pharmacy and Technology. 2022; Mar 1; 15(3): 1337-42. DOI: 10.52711/0974-360X.2022.00223
10. Liu L, Xu X. Preparation of bilayer-core osmotic pump tablet by coating the indented core tablet. International journal of pharmaceutics. 2008; Mar 20; 352(1-2): 225-30. https://doi.org/10.1016/j.ijpharm.2007.10.047
11. Akhtar M, Jamshaid M, Zaman M, Mirza AZ. Bilayer tablets: A developing novel drug delivery system. Journal of Drug Delivery Science and Technology. 2020; Dec 1; 60: 102079. https://doi.org/10.1016/j.jddst.2020.102079
12. Deshpande RD, Gowda DV, Mahammed N, Maramwar DN. Bi-layer tablets-An emerging trend: a review. International Journal of Pharmaceutical Sciences and Research. 2011; Oct 1; 2(10): 2534.
13. Li SP, Karth MG, Feld KM, Di Paolo LC, Pendharkar CM, Williams RO. Evaluation of bilayer tablet machines—a case study. Drug Development and Industrial Pharmacy. 1995; Jan 1; 21(5): 571-590. https://doi.org/10.3109/03639049509048124
14. Chauhan M, Suthar S, Shah A, Polara M, Patel M, Patel J. Bilayer tablet: Immediate release and sustain release: A review. Research Journal of Pharmacy and Technology. 2012; 5(6): 716-720
15. Kaur Bhatia J, Kaur R, Singh S. Formulation and optimization of hydrochlorothiazide mouth dissolving tablets by using co-processed superdisintegrants. Int J Pharm Sci Rev Res. 2013; 21(2): 46-51.
16. Purushothaman P, Sha A, Vetrichelvan T. Formulation development and Evaluation of immediate and sustained release Bilayer Tablets Containing Amitriptyline HCl and Pregabalin for the treatment of Neuropathic Pain. Asian Journal of Pharmacy and Technology. 2017; 7(3): 127-36.
17. Pandey P, Dahiya M. Oral disintegrating tablets: a review. International Journal of Pharma Research and Review. 2016; Jan; 5(1): 50-62.
18. Mayuri B. Patil, Priyanka M. Salve, Shital V. Sonawane, Avish D. Maru, Jayshree S. Bhadane, Rajendra K. Surawase. Technologies in Bilayer Tablet Manufacturing: A Review. Research Journal of Pharmaceutical Dosage Forms and Technology. 2021; 13(3):253-258. doi: 10.52711/0975-4377.2021.00042
19. Kumar PA, Surendrabhoopathi G, Kulakarni SV. Current Innovation in Layered Tablet Technology. Asian Journal of Research in Pharmaceutical Science. 2013; 3(4): 189-94. DOI: 10.52711/2231-5659
20. Ratnaparkhi MP, Gupta Jyoti P. Sustained release oral drug delivery system-an overview. Terminology. 2013; 3(4): 10-22270.
21. Gupta, M.M. and Brijesh, R. A review on: sustained release technology. International Journal of Therapeutic Application. 2012; 8(1):1-23.
22. Chauhan M, Suthar S, Shah A, Polara M, Patel M, Patel J. Bilayer tablet: Immediate release and sustain release: A review. Research Journal of Pharmacy and Technology. 2012; 5(6): 716-20.
23. Venkat Thota. Sustained release oral drug delivery system-an overview. International Journal of Pharma Research. 2015; 2(3): 11-21.
24. Garna, S., Chaturvedi, S., Agrawal, V. and Alim, M. Formulation approaches for sustained release dosage forms: a review. Asian J Pharm Clin Res. 2015; 8(5): 46-53.
25. Shukla S, Pandya V, Bhardia P, Jonwal N, Bhatt D. Bi-layer Tablet system–An Innovative trend. Asian Journal of Pharmaceutical Research. 2013; 3(2): 49-56.
26. Stieger N, Liebenberg W, Wessels JC. UV spectrophotometric method for the identification and solubility determination of nevirapine. Die Pharmazie. 2009; Oct 1; 64(10): 690-691. Die Pharmazie, 01 Oct 2009, 64(10):690-691
27. Thimmasetty J, Subrahmanyam CV, Vishwanath BA, Babu PR. Solubility parameter estimation of celecoxib by current methods. Asian Journal of Research in Chemistry. 2009; 2(2): 188-195.
28. Karajgi SR, Metri S, Tiwari V, Hulyalkar S, Rub TA, Patil AS. UV spectrophotometric method for the quantitative estimation of celecoxib in capsule dosage forms. Der Pharmacia Lettre. 2016; 8(10): 247-257.
29. Kumar P, Chaudhary M, Bhattacharya S, Juyal V. Validated Analytical Method Development of Celecoxib in Bulk, Tablet and Rat Plasma by UV-Spectroscopy. Research Journal of Pharmacy and Technology. 2010; 3(3): 894-6.
30. Primo FT, Fröhlich PE. Celecoxib identification methods. Acta Farmaceutica Bonaerense. 2005;24(3):421.
31. Bunaciu AA, Aboul-Enein HY, Fleschin S. Application of Fourier transform infrared spectrophotometry in pharmaceutical drugs analysis. Applied Spectroscopy Reviews. 2010; May 17; 45(3): 206-219. https://doi.org/10.1080/00387011003601044
32. Ford JL, Timmins P. Pharmaceutical thermal analysis: techniques and applications. 1989 Jan. https://lccn.loc.gov/88037189
33. Momin MM, Kane S, Abhang P. Formulation and evaluation of bilayer tablet for bimodal release of venlafaxine hydrochloride. Frontiers in pharmacology. 2015; Jul 9; 6: 144. https://doi.org/10.3389/fphar.2015.00144
34. Jadhav SB, Mali AD, Rajeghadage SH, Bathe RS. Formulation and evaluation of immediate release tablets of Imipramine hydrochloride. Int. J. Biomed. Adv. Res. 2014; 5(11):559-565. DOI:10.7439/ijbar
35. Shanmugam S, Chakrahari R, Sundaramoorthy K, Ayyappan T, Vetrichelvan T. Formulation and evaluation of sustained release matrix tablets of Losartan potassium. Int J Pharm Tech Res. 2011; Jan; 3(1): 526-534.
36. Lachman L, Lieberman HA, Kanig JL. The theory and practice of industrial pharmacy. Philadelphia: Lea and Febiger; 1976.
37. Nilawar PS, Wankhade V, Badnag D. An emerging trend on bilayer tablets. Int J Pharm Pharm Sci Res. 2013; 3(1): 15-21.
38. Nyol S, Gupta MM. Immediate drug release dosage form: a review. Journal of Drug Delivery and Therapeutics. 2013; Mar 15; 3(2).
39. Kavitha K, Kumar MR, Dakshayani S, SD JS. Bilayer tablet technology: An overview. Journal of Applied Pharmaceutical Science. 2011; Oct 30(Issue): 43-7.
40. Parashar B, Chauhan A, Prashar D, Chandel A, Kumar H, Purohit R. Formulation and evaluation aspects of tablets-An overview. Am J PharmTech Res. 2012; 2(1): 2249-3387.
41. Pharmacopoeia I. Government of India, Ministry of Health and Family Welfare, Controller of Publication, New Delhi, India, Vol. 1-2. Received 14th September 2014 Revised 21st September 2014 Accepted 26th September 2014 J. App. Pharm. Res. 2007; XI (4): 17-23.
42. Agarwal RK, Jain HK, Singhai AK. Estimation of Losartan potassium from tablets. Indian Drugs. 2000; 37(5):26-30.
43. Yeole P, Galgatte U, Babla I, Nakhat P. Design and evaluation of xanthan gum-based sustained release matrix tablets of diclofenac sodium. Indian Journal of Pharmaceutical Sciences. 2006 Mar 1; 68(2).
44. Brniak W, Jachowicz R, Pelka P. The practical approach to the evaluation of methods used to determine the disintegration time of orally disintegrating tablets (ODTs). Saudi Pharmaceutical Journal. 2015; Sep. 1; 23(4): 437-43. https://doi.org/10.1016/j.jsps.2015.01.015
45. M. Kaur, G. Kaur, S. Sharma, H. Kaur. Overview on stability studies. International Journal of Pharmaceutical, Chemical and Biological Sciences. 2013; Nov. 3(4): 1231-41. https://doi.org/10.1080/25740881.2020.1844233